Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale.
Berg
Alfred O
AO
U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Center for Practice and Technology Assessment, 6010 Executive Boulevard, Suite 300, Rockville, MD 20852, USA. uspstf@ahrq.gov
D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D002764:Cholecystitis / Q000139:chemically induced / Q000517:prevention & control; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000592:standards*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D017698:Postmenopause / Q000187:drug effects*; D011322:Primary Prevention / Q000592:standards*; D012307:Risk Factors